Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

2016 De Novo Classifications

This article was originally published in The Gray Sheet

Executive Summary

A sortable and searchable table of de novo classification decisions in calendar year 2016, updated monthly. Latest update: decisions through March 31.

You may also be interested in...



Amneal Expects Host Of New Launches To Drive Firm To Success

Despite a couple of setbacks during Q2, Amneal has sustained continual growth across its business, particularly in the injectables space.

Dr Reddy’s Gears For Generic Revlimid Run In US, Quarterly ‘Blips’ Aside

Quarterly ups and down notwithstanding, Dr Reddy’s signals continuing US launch momentum, with its generic Revlimid, for which the Indian firm claims exclusivity for two strengths, set to hit the market next month. “Low competition” assets, especially injectables, also continue to be on the deal-making radar in the US.

Shionogi Reveals Strategy For COVID-19 Drug Xocova

Shionogi is hoping to demonstrate the efficacy of its oral COVID-19 candidate Xocova through an appropriate primary endpoint in its Phase III trial, while the Japanese firm is also eyeing global expansion for the drug should a world-first domestic approval be granted.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT034676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel